Drug Trial Radar · NCT06969352
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Actual
Start
Sep 2, 2025
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Institut de Recherches Internationales Servier (I.R.I.S.); Hainan Boyan Medical Research Co. Ltd.; Fantastic Bioimaging Co., Ltd.; Clinical TrialService (Guangzhou) Co.,Ltd
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1/2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness of Vorasidenib in glioma patients treated in routine clinical practice in In China, patients aged 12 and above with grade II or higher astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. The main question it aims to answer is: if this trend is consistent with the efficacy observed in the INDIGO study, and there is not any new safety signal compared to previous research data? Researchers will compare to no treatment. Participants is not mandatory for a formal visit as it is a real-word study.However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice. This study is a multicenter, retrospective-and prospective real-world study, There are treatment group (Vorasidenib) and external control group (untreated after surgery).
Conditions
- Gliomas
Interventions
VorasidenibDrug
Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older: * For patients weighing at least 40 kg: 40 mg, orally, once daily. * For patients weighing less than 40 kg: 20 mg, orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy endpointTime frame: at 6 months after the index date
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
West China Lecheng Hospital Sichuan University
Qionghai, Hainan, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.